Biotechnology company Nucleome Therapeutics is set to advance a potential first-in-class treatment for major chronic inflammatory diseases. 

NTP464 is a potential first-in-class monoclonal antibody agonist with strong potency, selectivity and developability characteristics. Nucleome has nominated NTP646 for development. 

The target of NTP464 is a novel inflammation checkpoint identified using Nucleome’s proprietary suite of genetic approaches. By understanding how genetic variation in patients suffering from autoimmune disease impacts the physical 3D interactions with protein-coding genes, Nucleome has uncovered a multi-cellular orchestrator of inflammation resolution with potential to move beyond current advanced therapeutics.  

The core mechanism of the target, which acts to resolve inflammation in healthy individuals, becomes dysregulated in patients with autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD). 

“2025 marked a year of great progress for Nucleome, both for our genetics discovery technology and pipeline,” said Dr Mark Bodmer, CEO of Nucleome. 

“Our lab-based technology, Micro Capture-C (MCC), combined with strategic deployment of machine learning and other computational methods, has advanced genetics to an unprecedented level by deciphering patterns of gene regulation from the 3D architecture of the genome. This has redefined what genetic variation can reveal about disease, for both drug target discovery and stratification of patient populations. 

 “We have created the most comprehensive physical map of molecular mechanisms in inflammatory disease and continue to enhance this with emerging data. This means we can now uncover causal drivers of disease in humans, in areas of the greatest unmet patient need.  

“The nomination of our first development candidate, NTP464, is a major step forward for Nucleome and is a powerful example of what is possible when our cutting-edge platform intersects with therapeutic design.” 

 

Bruno Quinney, Content Team, DDW